1-7 of 7
depressed level of consciousness
Close
Sort by
Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, MD PhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jeffrey A. Barnes, MD PhD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio Chavez, Johannes Duell, MD, Kevin A. David, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Robert Charnas, PhD, Srikanth R. Ambati, MBBS, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Min Zhu, PhD, Jingjin Li, PhD, Peter Gasparini, MS, Anfal Ibrahim, BS, Vladimir Jankovic, MD, Nathalie Fiaschi, PhD, Olulanu Aina, PhD, Wen Zhang, PhD, Raquel P. Deering, PhD, Sara Hamon, PhD, Gavin Thurston, PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 762.
https://doi.org/10.1182/blood-2019-122451
Published: 2019
Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5079.
https://doi.org/10.1182/blood-2019-122745
Published: 2019
Journal Articles

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Giovanni Martinelli, MD, Hervé Dombret, Patrice Chevallier, MD PhD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Max S. Topp, MD, Adele K. Fielding, MB BS, PhD, Lulu Ren Sterling, PhD, Jonathan Benjamin, MD, Anthony Selwyn Stein, MD
Journal: Blood
Blood (2015) 126 (23): 679.
https://doi.org/10.1182/blood.V126.23.679.679
Published: 2015
Journal Articles

Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma

Joseph R. Mikhael, MD, Craig B. Reeder, MD, Edward N. Libby, III, MD, Luciano J. Costa, MD, PhD, P. Leif Bergsagel, M.D., Francis Buadi, MD, Angela Mayo, PA, Katherine Gano, Cassandra Wolf, Amylou Constance Dueck, PhD, A. Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 445.
https://doi.org/10.1182/blood.V120.21.445.445
Published: 2012
Journal Articles

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

A. Keith Stewart, Suzanne Trudel, MD, MSC, FRCPC, Nizar J Bahlis, MD, Darrell J White, MD, Waleed Sabry, MSc, MD, Andrew Belch, MD, Tony Reiman, MD, Jean Roy, MD, FRCPC, Chaim Shustik, MD, Michael J. Kovacs, MD, FRCPC, Jonathan Sussman, Ralph M. Meyer, MD, Erica L Harnett, M.Sc., Danila Oana, Judy A Chapman, Lois Shepherd, MD
Journal: Blood
Blood (2010) 116 (21): 39.
https://doi.org/10.1182/blood.V116.21.39.39
Published: 2010
Journal Articles

Phase I Study of Noscapine for Patients with Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy.

Anil Tulpule, MD, Alexandra M. Levine, MD, Nancy E. Berman, RN, BSN, Lynne Smith, PhD, Alan Auerbach, Dan Douer, MD
Journal: Blood
Blood (2005) 106 (11): 3341.
https://doi.org/10.1182/blood.V106.11.3341.3341
Published: 2005
Journal Articles

CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL.

Myron S. Czuczman, MD, Pierluigi Porcu, MD, Jeff Johnson, Donna Niedzwiecki, George P. Canellos, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2004) 104 (11): 2486.
https://doi.org/10.1182/blood.V104.11.2486.2486
Published: 2004